Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL462082 | 0.84 | CYP3A4 (0.46) | CYP3A4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8773347 | 0.77 | CYP3A4 (0.39) | CYP3A4 | |
| SCHEMBL9676287 | 0.77 | CYP3A4 (0.39) | CYP3A4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7770110 | 0.76 | CYP3A4 (0.35) | CYP3A4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL20599288 | 0.76 | CYP3A4 (0.42) | CYP3A4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL7768570 | 0.75 | CYP3A4 (0.38) | CYP3A4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL27539864 | 0.75 | CYP3A4 (0.38) | CYP3A4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4191136 | 0.75 | CYP3A4 (0.38) | CYP3A4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL27797024 | 0.75 | CYP3A4 (0.38) | CYP3A4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8958844 | 0.75 | CYP3A4 (0.46) | CYP3A4HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528278-B2 | Transesterification process for production of (meth)acrylate ester monomers | ROHM AND HAAS COMPANY (US) | 2009-05-05 | — | — | US | claimed |
| EP-1867637-A2 | Transesterification process for production of (meth)acrylate ester monomers | Rohm and Haas Company (US) | 2007-12-19 | — | — | EP | claimed |
| US-20070287841-A1 | Transesterification process for production of (meth)acrylate ester monomers | ROHM AND HAAS COMPANY | 2007-12-13 | — | — | US | claimed |
| US-20060173191-A1 | Transesterification process for production of (meth)acrylate ester monomers | CURTIS MICHAEL A | 2006-08-03 | — | — | US | claimed |
| EP-1686118-A1 | Transesterification process for production of (meth)acrylate ester monomers | Rohm and Haas Company (US) | 2006-08-02 | — | — | EP | claimed |
| US-6515138-B2 | Reacting an (meth)acrylate ester with an hydroxyalkylimidazolidin-2-one compound in presence of catalyst and polymerization inhibitor | ROHM AND HAAS COMPANY | 2003-02-04 | — | — | US | claimed |
| US-20020177719-A1 | Transesterification process | ROHM AND HAAS COMPANY | 2002-11-28 | — | — | US | claimed |
| EP-1241163-A1 | Transesterification process | ROHM AND HAAS COMPANY (US) | 2002-09-18 | — | — | EP | claimed |
| US-5066688-A | Hydroxyalkyl ethyleneurea, epoxy-amine resin, improved cure and chip resistance | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-11-19 | — | — | US | claimed |
| US-9416092-B2 | Transesterification process | ROHM AND HAAS COMPANY (US) | 2016-08-16 | — | — | US | disclosed |
| US-9394224-B2 | Transesterification process | ROHM AND HAAS COMPANY (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150045578-A1 | TRANSESTERIFICATION PROCESS | ROHM AND HAAS COMPANY (US) | 2015-02-12 | — | — | US | disclosed |
| US-20150045583-A1 | TRANSESTERIFICATION PROCESS | ROHM AND HAAS COMPANY (US) | 2015-02-12 | — | — | US | disclosed |
| EP-2825520-A1 | TRANSESTERIFICATION PROCESS | Rohm and Haas Company (US) | 2015-01-21 | — | — | EP | disclosed |
| US-6515138-B2 | Reacting an (meth)acrylate ester with an hydroxyalkylimidazolidin-2-one compound in presence of catalyst and polymerization inhibitor | ROHM AND HAAS COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-20020177719-A1 | Transesterification process | ROHM AND HAAS COMPANY | 2002-11-28 | — | — | US | disclosed |
| US-20020177719-A1 | Transesterification process | ROHM AND HAAS COMPANY | 2002-11-28 | — | — | US | disclosed |
| CN-1375491-A | Ester exchange method | ROHM & HAAS (US) | 2002-10-23 | — | — | CN | disclosed |
| EP-1241163-A1 | Transesterification process | ROHM AND HAAS COMPANY (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1241163-A1 | Transesterification process | ROHM AND HAAS COMPANY (US) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287841-A1 | Transesterification process for production of (meth)acrylate ester monomers | METTL14, MMAB, TET1 | CYP3A4 113/4885HDAC3 3315/4885HDAC4 1906/4885 |
| US-20020177719-A1 | Transesterification process | CES2, MAT2B, CYP4F2 | CYP3A4 14/4885HDAC3 3789/4885HDAC4 1744/4885 |
| US-20150045583-A1 | TRANSESTERIFICATION PROCESS | ADH5, ADH1A, MMAB | CYP3A4 7/4885HDAC3 4317/4885HDAC4 2752/4885 |
| US-20150045578-A1 | TRANSESTERIFICATION PROCESS | ADH1A, ADH5, ADH1C | CYP3A4 11/4885HDAC3 4419/4885HDAC4 3510/4885 |
| US-20060173191-A1 | Transesterification process for production of (meth)acrylate ester monomers | MMAB, METTL14, MTR | CYP3A4 80/4885HDAC3 3653/4885HDAC4 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.